[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results].
Reijers
M H
MH
Weverling
G J
GJ
Jurriaans
S
S
Wit
F W
FW
van Leeuwen
R
R
Bruisten
S M
SM
Frissen
P H
PH
Weigel
H M
HM
Mulder
J W
JW
ten Kate
R W
RW
de Wolf
F
F
Schuitemaker
H
H
Lange
J M
JM
D000998:Antiviral Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008297:Male; D019888:Nelfinavir / Q000008:administration & dosage*; D010865:Pilot Projects; D019258:Saquinavir / Q000008:administration & dosage*; D018119:Stavudine / Q000008:administration & dosage*; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D019259:Lamivudine; D018119:Stavudine; D019888:Nelfinavir; D019258:Saquinavir